| Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2) (NCT04202679) | Sanofi | 2020-01-16 |
| Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME) (NCT04183335) | Sanofi | 2019-12-12 |
| Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID) (NCT04180488) | Sanofi | 2019-12-11 |
| Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male Subjects (NCT04171310) | Sanofi | 2019-11-13 |
| Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (NCT04059484) | Sanofi | 2019-10-22 |
| A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) (NCT04074187) | Sanofi | 2019-10-21 |
| Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients (NCT04075513) | Sanofi | 2019-10-09 |
| A Prospective and Retrospective Cohort Study in Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD) (NCT04106544) | Sanofi | 2019-09-27 |
| Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis (NCT03996291) | Sanofi | 2019-09-23 |
| SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients" (NCT04033367) | Sanofi | 2019-08-22 |
| First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma (NCT04000282) | Sanofi | 2019-08-19 |
| Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) (NCT04045795) | Sanofi | 2019-08-06 |
| Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (NCT03860844) | Sanofi | 2019-08-06 |
| Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea (NCT03770728) | Sanofi | 2019-08-01 |
| Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive (NCT03794336) | Sanofi | 2019-06-29 |
| Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) (NCT03992417) | Sanofi | 2019-06-11 |
| Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease (NCT03437720) | Sanofi | 2019-05-23 |
| Sotagliflozin Multiple-dose Study in Healthy Chinese Subjects (NCT03909451) | Sanofi | 2019-04-28 |
| First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects (NCT04521738) | Sanofi | 2019-04-25 |
| Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation (NCT03930732) | Sanofi | 2019-04-15 |
| Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY) (NCT03849716) | Sanofi | 2019-04-05 |
| Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis (NCT03889639) | Sanofi | 2019-03-29 |
| To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis (NCT03856619) | Sanofi | 2019-03-27 |
| A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 Diabetes (NCT03903016) | Sanofi | 2019-03-26 |
| Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2) (NCT03816839) | Sanofi | 2019-03-25 |
| Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine (NCT03874715) | Sanofi | 2019-03-11 |
| Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM) (NCT03767543) | Sanofi | 2019-03-11 |
| Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin (NCT03798080) | Sanofi | 2019-02-19 |
| Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s) (NCT03798054) | Sanofi | 2019-02-15 |
| A Bioequivalence Study Testing Two Formulations of Sotagliflozin in Healthy Male and Female Subjects Under Fasted Conditions (NCT03776227) | Sanofi | 2019-01-25 |
| Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma (NCT03782532) | Sanofi | 2019-01-25 |
| Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female Subjects (NCT03802487) | Sanofi | 2019-01-14 |
| A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors (NCT03871348) | Sanofi | 2019-01-03 |
| Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis (NCT03912259) | Sanofi | 2018-12-19 |
| Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin (NCT03760991) | Sanofi | 2018-12-18 |
| Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis (NCT03757351) | Sanofi | 2018-12-14 |
| A Study of Isatuximab-based Therapy in Participants With Lymphoma (NCT03769181) | Sanofi | 2018-12-11 |
| Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea (NCT03761134) | Sanofi | 2018-11-30 |
| Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise (NCT03760965) | Sanofi | 2018-11-27 |
| Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA (NCT03600805) | Sanofi | 2018-11-20 |
| Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s) (NCT03713684) | Sanofi | 2018-11-09 |
| Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma (NCT03733717) | Sanofi | 2018-10-22 |
| Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and Above (NCT05406180) | Sanofi | 2018-10-10 |
| Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica (NCT03600818) | Sanofi | 2018-10-09 |
| Study of Excretion Balance and Pharmacokinetics of [14C]-Sodium Valproate (3.7 MBq) in Healthy Postmenopausal or Permanently Sterile Female Subjects (NCT03681158) | Sanofi | 2018-10-05 |
| Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin (NCT03684642) | Sanofi | 2018-09-26 |
| Study Evaluating the Efficacy and Safety of Fexofenadine in Subjects Suffering From Seasonal Allergic Rhinitis in Presence of Pollutants (NCT03664882) | Sanofi | 2018-09-17 |
| Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefenomel and Ferroquine in Patients With Uncomplicated Plasmodium Falciparum Malaria (NCT03660839) | Sanofi | 2018-09-11 |
| Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up) (NCT03620747) | Sanofi | 2018-08-30 |
| A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS) (NCT02991469) | Sanofi | 2018-08-09 |
| Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies (NCT03637764) | Sanofi | 2018-08-06 |
| Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (NCT03546907) | Sanofi | 2018-07-16 |
| Efficacy and Safety Study of New Ambroxol Hardboiled Lozenges in Acute Pharyngitis (NCT03583658) | Sanofi | 2018-06-30 |
| Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion) (NCT03560466) | Sanofi | 2018-06-21 |
| Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India) (NCT03529123) | Sanofi | 2018-06-19 |
| An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (NCT03510884) | Sanofi | 2018-05-31 |
| An Observational Study on Sarilumab-exposed Pregnancies (NCT03378219) | Sanofi | 2018-05-18 |
| Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis (NCT03375047) | Sanofi | 2018-05-10 |
| A Study to Assess Primarily the Tolerability and Safety of SAR439794 After Repeated Sublingual Daily Administration in Peanut Allergic Adult and Adolescent Patients (NCT03463135) | Sanofi | 2018-05-07 |
| Effect of Efpeglenatide on Cardiovascular Outcomes (NCT03496298) | Sanofi | 2018-04-27 |
| A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects (NCT03376802) | Sanofi | 2018-04-18 |
| Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3 (NCT03485677) | Sanofi | 2018-04-11 |
| Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy (NCT03415178) | Sanofi | 2018-03-29 |
| Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension (NCT03462069) | Sanofi | 2018-03-12 |
| Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus (NCT03462017) | Sanofi | 2018-03-07 |
| Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost. (NCT03703869) | Sanofi | 2018-03-06 |
| Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis (NCT03449758) | Sanofi | 2018-03-05 |
| Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (NCT03194867) | Sanofi | 2018-02-21 |
| Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents (NCT03434119) | Sanofi | 2018-02-20 |
| Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL (NCT03406000) | Sanofi | 2018-01-22 |
| Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy (NCT03359837) | Sanofi | 2018-01-20 |
| A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period (NCT03414736) | Sanofi | 2018-01-19 |
| Acne Vulgaris Related Microbiology and Serology (NCT04056598) | Sanofi | 2018-01-18 |
| A Drug-Drug Interaction Study Between Sotagliflozin and Ramipril (NCT03414723) | Sanofi | 2018-01-15 |
| Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies (NCT03367819) | Sanofi | 2018-01-04 |
| A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide (NCT03387657) | Sanofi | 2018-01-03 |
| A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers (NCT06188325) | Sanofi | 2018-01-01 |
| A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients (NCT03350191) | Sanofi | 2017-12-20 |
| Comparison of Exposure and Activity of SAR341402 Mix 70/30 to NovoLog Mix 70/30, NovoMix 30 and SAR341402 Rapid-acting Solution in Patients With Type 1 Diabetes Mellitus (NCT03916601) | Sanofi | 2017-12-13 |
| A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (NCT03319667) | Sanofi | 2017-12-07 |
| Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years (NCT03344029) | Sanofi | 2017-11-03 |
| Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients (NCT03275285) | Sanofi | 2017-10-25 |
| Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy Subjects (NCT03310944) | Sanofi | 2017-10-18 |
| Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors (NCT03324113) | Sanofi | 2017-10-17 |
| Association of Type 1 Diabetes Mellitus in Offsprings With Positive Parental History of Diabetes (NCT03312478) | Sanofi | 2017-10-13 |
| A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI (NCT03236311) | Sanofi | 2017-10-12 |
| Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer (NCT03284957) | Sanofi | 2017-09-20 |
| Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy) (NCT03260868) | Sanofi | 2017-09-19 |